ARDSLEY, N.Y.–(BUSINESS WIRE)–Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that it is discontinuing its clinical development program for tozadenant, an investigational treatment for Parkinson’s disease, including immediately discontinuing dosing of all participants currently enrolled in its tozadenant studies. The Company made this decision based on new information obtained from the Phase …
Tag Archives: PD
November, 2017
-
15 November
Acorda Halts Enrollment in Late-Stage Parkinson’s Disease Trial Following Five Patient Deaths
ARDSLEY, N.Y.–(BUSINESS WIRE)– Acorda Therapeutics, Inc.(Nasdaq:ACOR) today announced that it has increased the frequency of blood cell count monitoring for participants to weekly in its Phase 3 program of tozadenant for Parkinson’s disease. The Company took this action in response to cases of agranulocytosis, possibly drug-related, and in some cases associated …
August, 2017
-
25 August
FDA Approves Adamas’ Gocovri for the Treatment of Dyskinesia in Parkinson’s Disease Patients
EMERYVILLE, Calif., Aug. 24, 2017 (GLOBE NEWSWIRE) — Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved GOCOVRI (amantadine) extended release capsules (previously ADS-5102) for treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. GOCOVRI, previously granted orphan drug status by …
March, 2017
-
22 March
FDA Approves Newron’s Xadago for Treatment of Patients with Parkinson’s Disease
Milan, Italy and Morristown, NJ, U.S.A., – March 21, 2017 – Newron Pharmaceuticals S.p.A. (“Newron”, SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain, and its partners Zambon S.p.A. and US WorldMeds, LLC, announced today …
February, 2017
-
13 February
Acorda Therapeutics’ Inhaled Drug Successfully Reduces Parkinson’s Disease Symptoms in Late-Stage Study
ARDSLEY, N.Y.–(BUSINESS WIRE)– Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced Phase 3 clinical data of CVT-301, showing a statistically significant improvement in motor function in people with Parkinson’s disease experiencing OFF periods. CVT-301 is an investigational, inhalable formulation of levodopa (L-dopa). It is being studied as a treatment for OFF periods …
March, 2016
-
23 March
The Hepatitis C-Parkinson’s Disease Link
An estimated 3.5 million Americans have chronic hepatitis C virus (HCV) infection, a contagious liver disease that can lead to cirrhosis and/or liver cancer. Meanwhile, an estimated one million Americans live with the progressive movement disorder of Parkinson’s disease. For the first time, research indicates that these two conditions could …